ARGATROBAN

Pre-Launch

argatroban

Gland Pharma

ANDAINJECTIONINJECTABLE

Lifecycle

Pre-Launch

Clinical Trials

Data completeness

3/8 — Basic

ARGATROBAN (argatroban) by Gland Pharma is site. Approved for for prophylaxis or treatment of thrombosis.

Drug data last refreshed 1mo ago

Mechanism of Action

site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C;…

Indications (1)

For prophylaxis or treatment of thrombosis

Clinical Trials (2)

NCT01246011Phase 4Terminated

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

Started Nov 2010

9 enrolled

Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody

NCT00039858Phase 4Completed

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Started Sep 2003

24 enrolled

ThrombocytopeniaThrombosis

Worked on ARGATROBAN at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.